ATE254119T1 - 3-(arylsulfonylamino)-tetrahydropyran-3- carbonsäure hydroxamide - Google Patents

3-(arylsulfonylamino)-tetrahydropyran-3- carbonsäure hydroxamide

Info

Publication number: ATE254119T1
Authority: AT; Austria
Prior art keywords: arylsulfonylamino; tetrahydropyran; carboxylic acid; acid hydroxamide; cancer
Prior art date: 1999-05-28

Application number

AT00925520T

Other languages

English (en)

Inventor

Lawrence Alan Reiter

Road

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-28

Filing date

2000-05-15

Publication date

2003-11-15

2000-05-15 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-11-15 Application granted granted Critical

2003-11-15 Publication of ATE254119T1 publication Critical patent/ATE254119T1/de

Links

AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
229940009456 adriamycin Drugs 0.000 abstract 1
229930013930 alkaloid Natural products 0.000 abstract 1
229940035676 analgesics Drugs 0.000 abstract 1
239000000730 antalgic agent Substances 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
238000002648 combination therapy Methods 0.000 abstract 1
229940111134 coxibs Drugs 0.000 abstract 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
229960005420 etoposide Drugs 0.000 abstract 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
229910052697 platinum Inorganic materials 0.000 abstract 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
229940063683 taxotere Drugs 0.000 abstract 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
229960004528 vincristine Drugs 0.000 abstract 1
-1 vincristine Natural products 0.000 abstract 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)

AT00925520T 1999-05-28 2000-05-15 3-(arylsulfonylamino)-tetrahydropyran-3- carbonsäure hydroxamide ATE254119T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13653099P	1999-05-28	1999-05-28
PCT/IB2000/000647 WO2000073295A1 (en)	1999-05-28	2000-05-15	3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides

Publications (1)

Publication Number	Publication Date
ATE254119T1 true ATE254119T1 (de)	2003-11-15

Family

ID=22473239

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00925520T ATE254119T1 (de)	1999-05-28	2000-05-15	3-(arylsulfonylamino)-tetrahydropyran-3- carbonsäure hydroxamide

Country Status (22)

Country	Link
US (1)	US6197810B1 (de)
EP (1)	EP1181286B1 (de)
JP (1)	JP3784645B2 (de)
AT (1)	ATE254119T1 (de)
AU (1)	AU4424000A (de)
BR (1)	BR0011539A (de)
CA (1)	CA2375524C (de)
DE (1)	DE60006523T2 (de)
DK (1)	DK1181286T3 (de)
DZ (1)	DZ3046A1 (de)
ES (1)	ES2208315T3 (de)
GT (1)	GT200000079A (de)
HN (1)	HN2000000074A (de)
MA (1)	MA26738A1 (de)
MX (1)	MXPA01012265A (de)
PA (1)	PA8495901A1 (de)
PE (1)	PE20010170A1 (de)
PT (1)	PT1181286E (de)
SV (1)	SV2001000086A (de)
TN (1)	TNSN00111A1 (de)
UY (1)	UY26167A1 (de)
WO (1)	WO2000073295A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040122011A1 (en) *	1998-12-23	2004-06-24	Pharmacia Corporation	Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
NZ520657A (en)	2000-03-21	2004-11-26	Procter & Gamble	Heterocyclic side chain containing, N-substituted metalloprotease inhibitors
HUP0300262A2 (hu) *	2000-03-21	2003-06-28	The Procter And Gamble Co.	Heterociklusos oldalláncot tartalmazó metalloproteáz inhibitorok
EP1265865A2 (de)	2000-03-21	2002-12-18	The Procter & Gamble Company	Difluorbuttersäure-derivate und ihre verwendung als metalloprotease-hemmer
US7019376B2 (en) *	2000-08-11	2006-03-28	Reflectivity, Inc	Micromirror array device with a small pitch size
US20030045449A1 (en) *	2001-08-15	2003-03-06	Pfizer, Inc.	Pharmaceutical combinations for the treatment of neurodegenerative diseases
GB0319069D0 (en) *	2003-08-14	2003-09-17	Glaxo Group Ltd	Therapeutically useful compounds
US20050058611A1 (en) *	2003-08-22	2005-03-17	L'oreal	Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight
CN102348697B (zh)	2009-01-12	2014-12-10	辉瑞股份有限公司	磺酰胺衍生物
WO2012004706A2 (en)	2010-07-09	2012-01-12	Pfizer Limited	Chemical compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
NZ336840A (en)	1997-02-03	2001-01-26	Pfizer Prod Inc	Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
PA8469501A1 (es) *	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico

2000
- 2000-05-15 AT AT00925520T patent/ATE254119T1/de not_active IP Right Cessation
- 2000-05-15 WO PCT/IB2000/000647 patent/WO2000073295A1/en not_active Ceased
- 2000-05-15 ES ES00925520T patent/ES2208315T3/es not_active Expired - Lifetime
- 2000-05-15 AU AU44240/00A patent/AU4424000A/en not_active Abandoned
- 2000-05-15 DK DK00925520T patent/DK1181286T3/da active
- 2000-05-15 HN HN2000000074A patent/HN2000000074A/es unknown
- 2000-05-15 DE DE60006523T patent/DE60006523T2/de not_active Expired - Fee Related
- 2000-05-15 JP JP2000621361A patent/JP3784645B2/ja not_active Expired - Fee Related
- 2000-05-15 CA CA002375524A patent/CA2375524C/en not_active Expired - Fee Related
- 2000-05-15 BR BR0011539-8A patent/BR0011539A/pt not_active IP Right Cessation
- 2000-05-15 EP EP00925520A patent/EP1181286B1/de not_active Expired - Lifetime
- 2000-05-15 MX MXPA01012265A patent/MXPA01012265A/es active IP Right Grant
- 2000-05-15 PT PT00925520T patent/PT1181286E/pt unknown
- 2000-05-19 PA PA20008495901A patent/PA8495901A1/es unknown
- 2000-05-24 TN TNTNSN00111A patent/TNSN00111A1/fr unknown
- 2000-05-24 MA MA25988A patent/MA26738A1/fr unknown
- 2000-05-24 DZ DZ000090A patent/DZ3046A1/xx active
- 2000-05-25 GT GT200000079A patent/GT200000079A/es unknown
- 2000-05-26 UY UY26167A patent/UY26167A1/es not_active Application Discontinuation
- 2000-05-26 US US09/579,059 patent/US6197810B1/en not_active Expired - Fee Related
- 2000-05-26 SV SV2000000086A patent/SV2001000086A/es not_active Application Discontinuation
- 2000-05-26 PE PE2000000507A patent/PE20010170A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
MXPA01012265A (es)	2002-07-30
PE20010170A1 (es)	2001-02-27
CA2375524C (en)	2006-11-28
MA26738A1 (fr)	2004-12-20
UY26167A1 (es)	2000-12-29
EP1181286A1 (de)	2002-02-27
HN2000000074A (es)	2001-02-02
TNSN00111A1 (fr)	2002-05-30
PT1181286E (pt)	2004-02-27
DZ3046A1 (fr)	2004-03-27
DE60006523D1 (de)	2003-12-18
JP2003500485A (ja)	2003-01-07
DK1181286T3 (da)	2004-02-16
BR0011539A (pt)	2002-02-26
EP1181286B1 (de)	2003-11-12
US6197810B1 (en)	2001-03-06
DE60006523T2 (de)	2004-08-12
ES2208315T3 (es)	2004-06-16
CA2375524A1 (en)	2000-12-07
SV2001000086A (es)	2001-11-08
PA8495901A1 (es)	2002-08-26
JP3784645B2 (ja)	2006-06-14
GT200000079A (es)	2001-11-16
AU4424000A (en)	2000-12-18
WO2000073295A1 (en)	2000-12-07

Publication	Publication Date	Title
BR9912944A (pt)	2001-05-08	Inibidores de tace
YU5201A (sh)	2003-07-07	Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp
AP9801174A0 (en)	1998-01-31	Cyclic sulfone derivatives.
TR200002951T2 (tr)	2001-01-22	(4-Arilsülfonilamino)-tetrahidropiran-4-karboksilik asit hidroksamitler
MY121754A (en)	2006-02-28	Arylsulfonylamino hydroxamic acid derivatives
YU37499A (sh)	2002-09-19	Derivati arilsulfonil hidroksamske kiseline
NO20025792D0 (no)	2002-12-02	Kinazolinderivater for behandling av tumorer
ATE254119T1 (de)	2003-11-15	3-(arylsulfonylamino)-tetrahydropyran-3- carbonsäure hydroxamide
DE60142913D1 (de)	2010-10-07	Arzneilösungen enthaltend modafinilverbindungen
ATE251618T1 (de)	2003-10-15	3-(arylsulfonylamino)-tetrahydrofuran-3- carbonsäure-hydroxamide
ECSP003494A (es)	2001-12-28	Hidroxiamidas de acidos 3- ( arilsulfonilamino)-tetrahidropiran-3-carboxilicos

Legal Events

Date	Code	Title	Description
2004-05-15	UEP	Publication of translation of european patent specification	Ref document number: 1181286 Country of ref document: EP
2008-02-15	REN	Ceased due to non-payment of the annual fee

Date

Code

Title

Description

2004-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1181286

Country of ref document: EP

2008-02-15

REN

Ceased due to non-payment of the annual fee